Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07403812 · ClinicalTrials.gov registry record · NA
Assessing DCog Short for Neurotoxicity in CAR-T
A NA study, sponsored by Beth Israel Deaconess Medical Center.
- Not yet
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT07403812 is a NA study that has not yet begun recruiting, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 40 participants.
The verdict
NCT07403812, a NA study, has not yet begun recruiting, sponsored by Beth Israel Deaconess Medical Center.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
The aim of this study is to determine the effectiveness of DCog Short, a self-reporting, iPad-based application tool, in assessing neurotoxicity in participants undergoing CAR-T cell therapy.
Interventions
- BEHAVIORAL DCog Short
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-07 |
| Est. Completion | 2027-08-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07403812
The ClinicalTrials.gov registry entry for NCT07403812 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DCog Short is the first listed.
NCT07403812 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07403812 about?
NCT07403812 is a clinical study titled "Assessing DCog Short for Neurotoxicity in CAR-T". The aim of this study is to determine the effectiveness of DCog Short, a self-reporting, iPad-based application tool, in assessing neurotoxicity in participants undergoing CAR-T cell therapy.
What is the current status of trial NCT07403812?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2026-07. Estimated completion is 2027-08-31.
What interventions are being tested in trial NCT07403812?
The interventions under investigation include: DCog Short (BEHAVIORAL).
Who is sponsoring clinical trial NCT07403812?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.